STIM VS RAIN Stock Comparison

Performance

STIM
10/100

STIM returned -72.04% in the last 12 months. Based on SPY's performance of -13.39%, its performance is below average giving it a score of 10 of 100.

RAIN
10/100

RAIN returned -82.29% in the last 12 months. Based on SPY's performance of -13.08%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

STIM
90/100

5 analysts offer 12-month price targets for STIM. Together, they have an average target of 8, the most optimistic target put STIM at 8 within 12-months and the most pessimistic has STIM at 8.

RAIN

"Analyst Price Targets" not found for RAIN

Sentiment

STIM
74/100

STIM had a bullish sentiment score of 74.22% across Twitter and StockTwits over the last 12 months. It had an average of 3.11 posts, 0.22 comments, and 0.44 likes per day.

RAIN

"Sentiment" not found for RAIN

Technicals

STIM
64/100

STIM receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

RAIN
71/100

RAIN receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

Earnings

STIM
24/100

STIM has missed earnings 4 times in the last 20 quarters.

RAIN
10/100

RAIN has missed earnings 5 times in the last 20 quarters.

Profit

STIM
10/100

Out of the last 20 quarters, STIM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

RAIN
10/100

Out of the last 15 quarters, RAIN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

STIM
33/100

STIM has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

RAIN
49/100

RAIN has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Neuronetics, Inc. Common Stock Summary

Nasdaq / STIM

Healthcare

Medical - Diagnostics & Research

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Rain Oncology Inc. Common Stock Summary

Nasdaq / RAIN

Healthcare

Biotechnology

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Power up your portfolio